90Y-edotreotide for metastatic carcinoid refractory to octreotide (Q34101554)

31 July 2017

90Y-edotreotide for metastatic carcinoid refractory to octreotide (English)

1 reference

31 July 2017

1 reference

6

Eric Van Cutsem

0 references

Sue O'Dorisio

3

M Sue O'Dorisio

0 references

Hakim Bouterfa

14

Hakim Bouterfa

1 reference

31 July 2017

2

Thomas M O'Dorisio

0 references

Yusuf Menda

Yusuf Menda

4

0 references

Francoise Borson-Chazot

Francoise Borson-Chazot

8

0 references

David Bushnell

David L Bushnell

1

0 references

Rodney J. Hicks

Rodney J Hicks

5

0 references

M Sue O'Dorisio

M Sue O'Dorisio

3

0 references

Ashley Grossman

12

Ashley B Grossman

1 reference

31 July 2017

Jean-Louis Baulieu

7

1 reference

31 July 2017

Lowell Anthony

9

1 reference

31 July 2017

Al B Benson

10

1 reference

31 July 2017

Kjell Oberg

11

1 reference

31 July 2017

Mary Connolly

13

1 reference

31 July 2017

Yong Li

15

1 reference

31 July 2017

Katherine A Kacena

16

1 reference

31 July 2017

Norman LaFrance

17

1 reference

31 July 2017

Stanislas A Pauwels

18

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Journal of Clinical Oncology

31 July 2017

1 reference

31 July 2017

28

1 reference

31 July 2017

1652-1659

1 reference

31 July 2017

10

1 reference

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Updated population-based review of carcinoid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

A 5-decade analysis of 13,715 carcinoid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Chemotherapy in the treatment of neuroendocrine malignant tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872330

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

28 October 2018

1 reference

12 December 2020

Use of somatostatin analog in management of carcinoid syndrome

1 reference

12 December 2020

Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center

1 reference

12 December 2020

Endocrine tumors of the gastrointestinal tract

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2009.22.8585

1 reference

31 July 2017

1 reference

31 July 2017

1 reference